LP
IBRX icon

LMR Partners’s ImmunityBio IBRX Stock Holding History

LMR Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3M Buy
+3,824,900
New +$26.2M 0.06% 162

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

LMR Partners's IBRX Position: Q1 2025 in Review

LMR Partners sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 47,402 shares — an estimated $144K sold.

LMR Partners first reported a position in IBRX in Q2 2019 and held it in 3 quarters. The position peaked at $121K in Q4 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • LMR Partners reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 47,402 ImmunityBio shares in Q1 2025, an estimated $144K.
  • LMR Partners first reported a position in ImmunityBio in Q2 2019 and held it in 3 quarters.
  • LMR Partners's ImmunityBio position peaked at $121K in Q4 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.